Repositioning Candidate Details
| Candidate ID: | R0669 |
| Source ID: | DB04985 |
| Source Type: | investigational |
| Compound Type: | biotech |
| Compound Name: | Tigapotide |
| Synonyms: | Tigapotide |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Tigapotide is a synthetic 15-mer peptide that is derived from the natural sequence of amino acids of the prostate secretory protein (PSP94), one of three predominant proteins found in human seminal fluid. |
| CAS Number: | 848084-83-3 |
| Molecular Weight: | |
| DrugBank Indication: | For the treatment of late stage Hormone Refractory Prostate Cancer (HRPC) for which no effective therapy currently exists. |
| DrugBank Pharmacology: | PCK3145 is a synthetic 15-mer peptide that is derived from the natural sequence of amino acids of the prostate secretory protein (PSP94), one of three predominant proteins found in human seminal fluid. PSP94 expression in the prostate is down regulated in patients with advanced prostate cancer, and believed to be a survival mechanism for the cancer cells. Results from an earlier trial conducted in the U.K. showed PCK3145 to be safe and well tolerated at all doses tested and further suggest that it also plays a role in preventing the metastatic process as measured by its effect on MMP-9 levels, a Gelatinase B enzyme involved in angiogenesis, tumor invasion and metastasis. |
| DrugBank MoA: | The mechanism of action and receptor for PCK3145 suggests PCK3145 to be a signal transduction inhibitor with multiple ways (apoptosis, anti-angiogenesis and anti-metastasis) to restrict disease development. |
| Targets: | 40S ribosomal protein SA |
| Inclusion Criteria: | Therapeutic strategy associated |
